# A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of CKD-333 or Co-administration of CKD-333 and D085 in Healthy Volunteers

> **NCT04627207** · PHASE1 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 51 (estimated)

## Conditions studied

- Cardiovascular Diseases

## Interventions

- **DRUG:** CKD-330 1 Tab. and D085 1 Tab.
- **DRUG:** CKD-333 1 Tab

## Key facts

- **NCT ID:** NCT04627207
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11
- **Primary completion:** 2021-03
- **Final completion:** 2021-04
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2020-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04627207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04627207, "A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of CKD-333 or Co-administration of CKD-333 and D085 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04627207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*